GO
Loading...

Enter multiple symbols separated by commas

Stocks Express Scripts Holding Co

More

  • *Zarxio priced at 15 pct less than Amgen's Neupogen. *Amgen unsuccessful in attempt to block Zarxio launch. The arrival of biosimilars threatens companies heavily reliant on biotech drugs, such as Amgen, AbbVie and Roche, and Citigroup analysts have predicted a transfer of at least $110 billion of value from innovator companies to copycat producers in the next...

  • ZURICH/ LONDON, Sept 3- Novartis kicked off a new era in U.S. medicine on Thursday with the launch of the first "biosimilar" copy of a biotechnology drug approved in the United States, following a green light from a U.S. appeals court. Novartis unit Sandoz said Zarxio, its form of Amgen's white blood cell-boosting product Neupogen, would increase access to an important...

  • Amgen wins approval for second biotech cholesterol drug Thursday, 27 Aug 2015 | 5:18 PM ET

    WASHINGTON— Amgen Inc. has won federal approval for the second medicine in a new class of pricey biotech drugs that reduce artery-clogging cholesterol more than older statin drugs that have been used for decades. Thousand Oaks, California- based Amgen priced the drug slightly below a similar drug Praluent, which costs $14,600 per year. Sanofi and partner...

  • Wal-Mart Stores Inc said on Tuesday that lower margins in its pharmacy business had emerged as a drag on profits, as it gets paid less by drug plan managers and as fewer customers pay in cash, since Obamacare has increased the ranks of insured Americans. The company warned that the margin squeeze would continue for at least the remainder of the year, although a...

  • Aug 17- Target Corp promoted Chief Financial Officer John Mulligan to the newly created role of chief operating officer, and appointed Express Scripts Holding Co's CFO, Cathy Smith, as his replacement. Smith, who will join on Sep. 1, has previously served as CFO of Wal-Mart Stores Inc's international division. The company in April named grocery retail veteran Anne...

  • Target promotes CFO Mulligan to COO Monday, 17 Aug 2015 | 9:01 AM ET

    Aug 17- Target Corp promoted Chief Financial Officer John Mulligan to the newly created role of chief operating officer, and appointed Express Scripts Holding Co's CFO Cathy Smith as his replacement.

  • Aug 5- CVS Health Corp, which operates the nation's second-biggest pharmacy benefit manager, said that next year it will exclude an additional 31 prescription medicines from insurance coverage, including Viagra and widely used treatments for diabetes and multiple sclerosis. The 2016 excluded drugs, disclosed on Wednesday, also include Vivus Inc's weight...

  • Aug 5- CVS Health Corp, which operates the nation's second-biggest pharmacy benefit manager, said that next year it will exclude an additional 31 prescription medicines from insurance coverage, including Viagra and widely used treatments for diabetes and multiple sclerosis. The 2016 excluded drugs, disclosed on Wednesday, also include Vivus Inc's weight...

  • July 29- Express Scripts Holding Co, the largest pharmacy benefit manager in the United States, on Wednesday said the cost of potent, newly approved cholesterol drugs could "wreak financial havoc" among its clients. Express Scripts, which administers drug benefits for employers and health plans and also runs large mail-order pharmacies, has been challenging...

  • July 29- Express Scripts Holding Co, the largest pharmacy benefit manager in the United States, on Wednesday said the cost of potent new cholesterol drugs called PCSK9 inhibitors could "wreak financial havoc" among its clients. U.S. regulators on Friday approved the first of the new medicines, Praluent from Regeneron Pharmaceuticals Inc and Sanofi SA.

  • Early movers: HLT, ANTM, ETN, TWTR, GSK & more Wednesday, 29 Jul 2015 | 7:54 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Top trades to go: Earnings edition Tuesday, 28 Jul 2015 | 1:43 PM ET

    The "Halftime Report" traders give their trades on earnings for the second half.

  • Minefield for market with Fed, earnings, commodities Monday, 27 Jul 2015 | 8:08 AM ET
    An oil trader works on the floor of the New York Mercantile Exchange.

    The Fed meets next week, but a commodities meltdown and earnings season are adding to concerns about global growth and may steal some of its thunder.

  • New heart drugs come in more expensive than expected Monday, 27 Jul 2015 | 6:02 AM ET

    *Sanofi, Novartis set high prices for Praluent, Entresto. Praluent, made by Sanofi and Regeneron Pharmaceuticals, and Entresto from Novartis are both treatments that represent significant advances for millions of patients at risk of serious heart problems. Sanofi and Regeneron, which won U.S. approval on Friday for Praluent to treat stubbornly high...

  • Risk on, risk off trades Wednesday, 1 Jul 2015 | 12:49 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Risk on, risk off trades

  • Trader beating market: Facebook breaking out Thursday, 25 Jun 2015 | 12:41 PM ET
    Facebook

    Josh Brown is selling out of three of his top holdings in favor of momentum names for the "Halftime Report" Portfolio.

  • Why a FDA nod isn't enough for Regeneron shares Wednesday, 10 Jun 2015 | 12:49 PM ET
    A technician at Regeneron Pharmaceuticals headquarters in Tarrytown, N.Y.

    Regeneron's shares sank 4 percent despite a positive Food and Drug Administration recommendation on a cholesterol drug. What gives?

  • Linking cancer drug prices to their performance Wednesday, 27 May 2015 | 1:54 PM ET

    Express Scripts is looking at the possibility of paying more for drugs that have been proven to show more benefit, and less where the drug hasn't.

  • Early movers: TIF, KORS, TOL, BWS, HRL & more Wednesday, 27 May 2015 | 8:31 AM ET
    Trader on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Assuming approval from the U.S. Food and Drug Administration, Amgen Inc. will offer its drug, Repatha, as a biweekly 140 mg injection or a monthly injection of 420 mg, while Praluent, from Regeneron Pharmaceuticals Inc and Sanofi, will be offered in biweekly injections of 75 mg or 150 mg. Regeneron and Sanofi could enjoy a significant pricing advantage with their...